Game-Based app aims to boost HPV vaccination in young cancer survivors
NCT ID NCT05665543
First seen Sep 02, 2026 · Last updated Sep 03, 2026 · Updated 1 time
Summary
This trial tests whether a game-based mobile app can increase HPV vaccination among young cancer survivors. Participants use the app to learn about HPV risks and get reminders to complete the vaccine series. The study includes survivors aged 18-26 and caregivers of younger survivors. The goal is to see if the app helps more people start and finish the three-dose HPV vaccine.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- A game-based mobile app (GLAm) that provides education and reminders to encourage HPV vaccination
- What this could lead to
- If it works, this app could help protect young cancer survivors from HPV-related cancers by increasing vaccination rates.
- What could go wrong
- The trial is relatively small and tests a behavioral intervention, so results may vary. Success depends on participants actually using the app and following through with vaccinations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
162 people
The number who actually took part.
- Started
-
Jul 2023
- Expected to finish
-
Oct 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
9 to 26 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Current patient in the University of Minnesota CCSP clinic or the Children's Minnesota Long-Term Follow-up (LTFU) Program clinic. * Patients seen in the CCSP clinic who do not have a history of cancer but who have received immunosuppressive therapy or HSCT for treatment of a hematologic disorder. * Survivor of childhood cancer (defined as diagnosed with cancer at age 25 years or younger) who is currently 18-26 years of age OR a caregiver of a survivor of childhood cancer who is currently 9-17 years of age. * 6+ months post-treatment; current treatment for graft-versus-host disease allowed * No previous HPV vaccination or incomplete HPV vaccination (defined as \<3 doses post-cancer therapy). Individuals who are unsure of their HPV vaccination status who are unable to find vaccination records per the procedures detailed in Section 5.2, EHR support will be eligible, in concordance with real-world clinical practice regarding HPV vaccination. Exclusion Criteria: * Previous completion of the HPV vaccination series. Those who are eligible for re-vaccination per the CDC guidelines will be encouraged by their oncologist to re-vaccinate, but will not be included in the QI study or RCT. * Unable to read/write in English per self-report (only applies to participants in the RCT \[Aim 2\]). * Pregnant at the time of enrollment or plans to become pregnant in the next year. Pregnancy test at the time of enrollment is not required if pregnancy not clinically suspected in concordance with clinical guidelines for HPV vaccine administration. * Currently receiving treatment for cancer or hematologic disorder or plan for treatment within 12 months of enrollment; treatment for graft-versus-host disease allowed. * Other contraindications to the HPV vaccine (e.g. history of immediate hypersensitivity reaction to any vaccine component, including yeast).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cancer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Minnesota Masonic Cancer Center
Minneapolis, Minnesota, 55455, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Évaluation de la détresse post-traumatique relative au cancer dans l'année suivant le diagnostic chez les patients et les aidants et identification de leurs attentes envers un accompagnement personnalisé
- A person-centred approach to pictorial support in care for children (PicPecc)
- Development and pilot implementation of a novel remote patient monitoring program for cancer patients initiating cancer-directed therapy: the SHIELD (Smart health integration for early life-saving detection)
- The promoting resilience in stress Management-Social needs (PRISM-SN) intervention for adolescents and young adults with cancer: a randomized controlled trial
- An equity focused intervention to improve utilization of guideline concordant extended venous thromboembolism prophylaxis after major cancer surgery
- The effect of gamified sleep hygiene education on sleep quality and fatigue levels in chemotherapy patients